by Jacob Harney, PhD | Mar 3, 2026 | Myeloma News
March is Myeloma Action Month (MAM), and organizations around the world are participating to support patients, families, and caregivers who live with myeloma. This year, the International Myeloma Foundation (IMF) is inviting members of the myeloma community to...
by MM360 Staff | Mar 3, 2026 | Publications
Front Pharmacol. 2026 Feb 12;16:1687718. doi: 10.3389/fphar.2025.1687718. eCollection 2025. ABSTRACT BACKGROUND: Cluster of differentiation 38 (CD38) monoclonal antibodies, including daratumumab and isatuximab, have demonstrated clinical activity in relapsed or...
by Marisa Wexler, MS | Mar 2, 2026 | Myeloma News
Early results from the Phase 2/3 MIRACLE clinical trial suggest that the experimental chemotherapy drug annamycin may offer meaningful benefit as a second-line treatment for people with relapsed or refractory acute myeloid leukemia (AML), an aggressive and often...
by MM360 Staff | Mar 2, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Feb 28, 2026 | Publications
Cancers (Basel). 2026 Feb 19;18(4):686. doi: 10.3390/cancers18040686. ABSTRACT Background: B-cell maturation antigen (BCMA) directed therapies have transformed the treatment landscape for relapsed or refractory multiple myeloma (RRMM). Soluble BCMA (sBCMA), a...
